Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: Quantitative analysis of HER2 overexpression effects

被引:0
|
作者
Hendriks, BS
Opresko, LK
Wiley, HS
Lauffenburger, D [1 ]
机构
[1] MIT, Dept Chem Engn, Biol Engn Div, Cambridge, MA 02139 USA
[2] MIT, Canc Res Ctr, Cambridge, MA 02139 USA
[3] Pacific NW Natl Lab, Environm & Hlth Sci Div, Richland, WA 99352 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Elevated expression of human epidermal growth factor receptor 2 (HER2) is known to alter cell signaling and behavioral responses implicated in tumor progression. However, multiple diverse mechanisms may be involved in these overall effects, including signaling by HER2 itself, modulation of signaling by epidermal growth factor receptor (EGFR), and modification of trafficking dynamics for both EGFR and HER2. Because these processes are so tightly interrelated, the net effect of HER2 overexpression is difficult to reliably attribute to any single particular mechanism. To take an important first step toward dissecting the effects of HER2 overexpression on cell responses in terms of the various specific underlying mechanisms, we have developed and validated a quantitative model of the relevant trafficking processes. We then use our model for successful prediction of EGFR and HER2 level and location changes attributable to HER2 overexpression in 184A1 human mammary epithelial cells expressing a series of HER2 levels by retroviral infection. Model predictions are based on our independent experimental measurement of key trafficking parameters for both EGFR and HER2. In terms of trafficking processes, HER2 overexpression reduces the EGFR internalization rate constant and increases the fraction of EGFR recycled. Consequently, our model successfully predicts that HER2 increases the overall level of activated EGFR by both enhancing its recycling and reducing its internalization, but it increases activated EGFR localization at the cell surface almost solely by its reduction of internalization. Furthermore, the model also successfully predicts the effects of monoclonal antibody 2C4, which interferes with HER2/EGFR heterodimerization, on EGFR and HER2 levels and compartmental locations. We anticipate that this model should ultimately be useful in parsing the relative contributions of direct effects of HER2 via signaling vis-a-vis indirect effects of HER2 via modification of EGFR signaling.
引用
收藏
页码:1130 / 1137
页数:8
相关论文
共 50 条
  • [21] Draft recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer will decrease HER2 positivity rates
    Johnson, Eric
    Gulbahce, Evin
    CANCER RESEARCH, 2018, 78 (04)
  • [22] The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
    Duran, C. Garcia
    Musacchio, L.
    Mazzeo, R.
    Carita, L.
    Jimenez, J.
    Bejar, J. F. Grau
    Illescas, D. G.
    Fasani, R.
    Madrid, L. Farinas
    Villacampa, G.
    Oaknin, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S590 - S591
  • [23] A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion
    Fichter, Christiane Daniela
    Przypadlo, Camilla Maria
    Buck, Achim
    Herbener, Nicola
    Riedel, Bianca
    Schaefer, Luisa
    Nakagawa, Hiroshi
    Walch, Axel
    Reinheckel, Thomas
    Werner, Martin
    Lassmann, Silke
    JOURNAL OF PATHOLOGY, 2017, 243 (04): : 481 - 495
  • [24] Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer
    García, I
    Vizoso, F
    Martín, A
    Sanz, L
    Abdel-Lah, O
    Raigoso, P
    García-Muñiz, JL
    ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (03) : 234 - 241
  • [25] Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer
    I. García
    F. Vizoso
    A. Martín
    L. Sanz
    O. Abdel-Lah
    P. Raigoso
    J. L. García-Muñiz
    Annals of Surgical Oncology, 2003, 10 : 234 - 241
  • [26] Human epidermal growth factor receptor families (EGFR, HER2) and survival in colorectal adenocarcinoma
    Molaei, M.
    Pejhan, S.
    Emami, S.
    Ghiasi, S.
    Mashayekhi, R.
    Zali, M.
    Motlagh, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 90 - 90
  • [27] Prognostic influence of preoperative plasma levels of Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) on disease outcomes following radical cystectomy
    Oberneder, K.
    Klemm, J.
    Schuettfort, V
    Laukhtina, E.
    Shariat, S. F.
    EUROPEAN UROLOGY, 2024, 85 : S875 - S876
  • [28] Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
    Riecke, Kerstin
    Witzel, Isabell
    BREAST CARE, 2020, 15 (06) : 579 - 585
  • [29] Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
    Siddiqui, Mohammad R.
    Railkar, Reema
    Sanford, Thomas
    Crooks, Daniel R.
    Eckhaus, Michael A.
    Haines, Diana
    Choyke, Peter L.
    Kobayashi, Hisataka
    Agarwal, Piyush K.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [30] Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
    Mohammad R. Siddiqui
    Reema Railkar
    Thomas Sanford
    Daniel R. Crooks
    Michael A. Eckhaus
    Diana Haines
    Peter L. Choyke
    Hisataka Kobayashi
    Piyush K. Agarwal
    Scientific Reports, 9